The tumor suppressor protein p53 is a transcription factor frequently inactivated in human cancers. We have studied the DNA binding potential and the transcriptional activity of p53 variants and p53 protein complexes in in vitro transcription assays. p53 speci®c transcription was measured via introduction of radioactive UTP into G-free cassette transcripts regulated by promoter sequences containing p53 response elements. Latent and activated p53 fractions were prepared from insect cells infected with p53 encoding baculoviruses by chromatography on heparin columns. p53 fractions distinguishable by their specifc DNA binding activities and their recognition by monoclonal antibody PAb421 were obtained. Speci®c DNA binding and binding to PAb421 are mutually exclusive. The C-terminus of p53 can be phosphorylated by casein kinase II, protein kinase C and cyclin dependent kinases. The antibody PAb421 binds within the PKC phosphorylation site of p53 and is able to activate DNA binding of latent p53 in vitro. Activation of p53 by PAb421 also results in enhanced transactivation in vitro. Dephosphorylation of latent p53 with phosphatase 2A does not change these properties. This suggests that a conformational change in the carboxyl terminal domain of p53 controls the transactivation potential of p53.
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The gene encoding the tumor suppressor p53 serves crucial protective functions in cells which prevent the acquisition and propagation of genetic aberrations (Lane, 1992) . Loss of these functions contributes frequently to cellular transformation. An important phenotype of p53 activation is cell cycle arrest, another one apoptosis. Both phenotypes are thought to impede replication of damaged DNA sequences and thus the ®xation of mutations, allowing for DNA repair upon cell cycle arrest or elimination of cells upon induction of apoptosis.
The domain structure of p53 has been established. It consists of a N-terminal transactivation domain, a central DNA binding domain and a C-terminal oligomerization domain (Bargonetti et al., 1993; Wang et al., 1994; Pavletich et al., 1993) . Secondary modi®cations have been discovered in the p53 molecule. p53 is phosphorylated at multiple serine and threonine residues. These modi®cations may play a role in the post-translational regulation of p53 and in¯uence the functional properties of the molecule. The N-terminal transactivation domain is phosphorylated by CKI (Fuchs et al., 1995) , by MAP kinase (Milne et al., 1994) , by raf kinase (Jamal and Zi, 1995) and by DNA-PK (Ullrich et al., 1993) . Speci®c mutations have been introduced into p53 to correlate phosphorylation with DNA binding and transactivation properties (for review : Meek, 1994; Lane et al., 1995) . It is conceivable that N-terminal phosphorylation of p53, catalyzed by enzymes like the DNA-PK activated upon DNA damage, may enhance the transactivation potency of p53. Phosphorylation may also alter the capability of MDM-2 to bind to p53 (Gudas et al., 1994) .
The C-terminus of p53 can be phosphorylated by CKII (Meek et al., 1990) , PKC (Hupp and Lane, 1994b; Skouv et al., 1994) , cdk (Wang and Prives, 1995) and p34 cdc2 (Addison et al., 1990) . The involvement of cell cycle dependent kinases suggests a dierential regulation of p53 activity in the cell cycle. The mutation of the CKII site (ser389ala) has been investigated and a loss of growth arresting properties (Milne et al., 1992) and a loss in transcriptional repression activity has been reported (Hall et al., 1996) . PKC isozymes phosphorylate p53 at the Cterminus in vitro. This region also comprises a basic domain with non-speci®c DNA binding properties and the epitope for the antibody PAb421. The consequences of PKC activation on p53 have been studied. Attenuation of DNA binding activity of p53 after TPA treatment and irradiation was observed (Price and Calderwood, 1993) . In vitro phosphorylation by several PKC isozymes activated DNA binding of p53 (Hupp and Lane, 1994b; Takenaka et al., 1995; our observations) . It is possible that PKC has a negative eect on p53 expression in vivo (Skouv et al., 1994) .
Further evidence for post-translational regulation of p53 activity was obtained in experiments with the monoclonal antibody PAb421. This antibody distinguishes between latent and activated p53 (Hupp et al., 1992 (Hupp et al., , 1993 . p53 encoded by a baculovirus vector produced in insect cells can be separated by heparin column chromatography into fractions with dierent DNA binding and PAb421 binding properties (Hupp and Lane, 1994a) . Activated p53, with a constitutive DNA binding activity, is correlated with the lack of PAb421 binding. This form is expressed, for example, in glioblastoma cells harboring an inducible p53 construct. The induced protein is not recognized by PAb421 and the cells undergo growth arrest after induction. The reason may be phosphorylation by PKC in the PAb421 epitope (Ullrich et al., 1992) . Other mechanisms have been described which allow the distinction between latent and activated p53. The elimination of 30 amino acids from the C-terminus of p53 results in a constitutively active DNA binding form (Hupp et al., 1992) . Speci®c DNA binding of p53 can also be activated by short single stranded or double stranded DNA fragments which bind to the basic C-terminus (Bakalkin et al., 1994; Jayaraman and Prives, 1995; Bayle et al., 1995; Molinari and Milner, 1995) . Additional mechanisms increase speci®c DNA binding of p53. The heat shock protein dnaK increases DNA binding activity of bacterially expressed p53 (Hupp et al., 1992; and peptides spanning a region within the last 30 amino acids of p53 activate DNA binding . These interactions might have a common basis; the interference with the C-terminus of p53 triggers a conformational change which releases inhibitory properties by the C-terminus and enhances speci®c DNA binding.
The role of secondary modi®cations and interactions with modulating components in the transactivation by p53 is dicult to assess in vivo. Speci®c cellular backgrounds and co-operating signals emenating from dierent signal transduction pathways can obscure the measurement of the transactivation properties of p53 in cells co-transfected with the p53 gene and a reporter construct. For example, signals which cause p53 activation in vivo, irradiation and DNA damage, also inhibit translation (Fritsche et al., 1993) . In vitro transcription can evade some of these diculties and latent or activated forms of p53 can be investigated directly in this assay system. In vitro transcription can validate and extend conclusions about the activity of p53 gained in DNA bandshift assays which measure the speci®c DNA binding capability of p53. If DNA binding and transactivation are, for example, separately regulated in vitro transcription assays might complement the conclusions obtained from DNA binding studies.
p53-dependent in vitro transcription with human, wildtype p53 puri®ed from baculovirus infected Sf9 cells
We established an in vitro transcription assay which allows us to eciently quantitate the transactivation potential of p53. We used promoter-indicator constructs which contain p53 response elements in their promoter regions and G-free cassettes in the transcribed region (Sawadogo and Roeder, 1985) . For this purpose, we constructed a reporter plasmid (BC-TATA G300, abbreviated BC300) containing synthetic p53 response elements (three copies of the high anity binding site BC) in its promoter region and a G-free cassette (300 bases) in its transcribed region. A constitutively active promoter (AdML), directing the transcription of a G-free cassette of a dierent length (200 bases; AdML200) was used as a control (Figure 1 ). We investigated the properties of recombinant p53 variants and compared it with the properties observed in bandshift assays. Figure 1 Plasmids employed in the in vitro transcription reactions. The sequence comprising three p53 response elements is shown. This sequence was integrated into a plasmid containing a minimal promoter sequence and a G-free cassette of 300 base pairs. The lower construct depicts the constitutively active template regulated by the adeno major late promoter. It directs the transcription of a G-free cassette of 200 base pairs. The p53 response elements were cloned into the BglII site of the pUC derived vector TATA G300 which contains a minimal promoter provided by the sequences 741 to 729 of the HSV TK gene and the 733 to 729 sequence of the chicken ovalbumine gene (Klein-Hitpass et al., 1991) . The promoter sequence recognized by p53 was a BC element . The oligonucleotides constitute a full double stranded BC element and a halfsite: 5'-GATCCCGGGCATGTCCGGGCATGTCCGGGCATGTA-3'; 5'-GATCTACATGCCCGGACATGCCCGGACATGCCCGG-3'. The mutant p53 response elements MG15 (Kern et al., 1992) were cloned into the vector TATA G200 (Klein-Hitpass et al., 1991). The constitutively active reporter for control of transcription was the pMLcas9 vector containing the adeno major late promoter (Sawadogo and Roeder, 1985) . The reporter plasmid contained a G-free cassette of 200 bp When the plasmids BC300 and AdML200 were introduced into the in vitro transcription reaction, only AdML200 was eciently transcribed. This is shown in the autoradiogram of the transcripts ( Figure 2a , lane 1) and the quantitation of the signals ( Figure 2b , lane 1). Addition of p53, puri®ed from insect cells infected with a p53 encoding baculovirus, into the in vitro transcription reaction, caused a strong induction of BC300 transcription, but did not aect AdML200 (Figure 2a and b, lane 2). PAb1801 is a monoclonal antibody which binds to the transactivation domain of p53. Inclusion of this antibody suppressed p53 induced transactivation, but had only a minor eect on AdML200 (Figure 2a and b, lane 3) .
Control experiments were carried out to validate the speci®city of the in vitro transcription reaction. A mutated p53 response element, which resembles the active one, but which has lost its p53 binding ability was derived from PG15-CAT (Kern et al., 1992) and cloned into the G-free cassette vector TATA G200. This construct was not induced by p53 and did not interfere with BC300 induction when both plasmids were present in the reaction (Figure 2a and b, lanes 4 and 5). A construct lacking p53 response elements (TATA G300) (Klein-Hitpass et al., 1991) was not activated by p53 (lanes 6 and 7). Inclusion of a doublestranded oligonucleotide, comprising the BC response element, resulted in the competition for binding to p53 and prevented the induction of BC300 (lanes 8 and 9). A double-stranded oligonucleotide unrelated to the p53 response element had no eect on p53 induction of BC300 (lanes 10 and 11). Crude extracts from Sf9 cells inhibited transactivation of the control plasmid and the p53 dependent reporter plasmid (lanes 12 and 13).
Activated and latent forms of p53 can be distinguished by binding to the p53 response element and recognition through the antibodies PAb421 and PAb1801
Expression of p53 can be achieved in Sf9 cells infected with a baculovirus vector encoding the protein. The radioactivity of the background in the vicinity of the speci®c signals was substracted from the activities of the reporter RNA fragments. De®nition of the components used: active p53 ± puri®ed from Sf9 extracts; PAb1801 ± monoclonal antibody directed against the N-terminal transactivation domain of p53; mt200 ± a control vector containing mutant p53 response elements; TATA300 ± a control vector without p53 response elements; BC ± oligonucleotide comprising the p53 response element; unrelated ± an oligonucleotide without sequence homology to a p53 response element (5'-ACAGGTACCCCATCGAATCCGGATC). The nuclear extract providing the transcription factors for the in vitro transcription assay was prepared from rat liver (Gorski et al., 1986; Kugler et al., 1990) . The assay conditions were described by Klein-Hitpass et al. (1991) and modi®ed for p53 transcription. The ®nal concentrations in a 20 microliter assay were: 5% glycerol, 25 mM HEPES, pH 7.9, 60 mM KCl, 6 mM MgCl 2 , 0.6 mM CTP, 0.6 mM ATP, 5 mM UTP, 0.1 mM a-methyl-GTP (Pharmacia, Freiburg), 2 mM DTT. The reaction mixture included 8 microliter rat liver nuclear extract, 15 U RNase T1 (Sigma, Munich), 16 U RNase inhibitor (Pharmacia, Freiburg), salmon sperm competitor DNA 200 ng, 40 ng control plasmid: pAdMLcas9, 400 ng BC-G300, 2.5 microCi [a-32 P]UTP. Preincubation with antibodies was carried out for 30 min at 228C, the transcription reaction was for 30 min at 308C. The reaction was terminated by the addition of 100 microliter of 0.5 % SDS, 25 mM Tris/HCl pH 7.5. 10 mM EDTA, 200 mg/ml t-RNA (Boehringer Mannheim) 400 mg/ml Proteinase K and incubation for 30 min 100 microliter of 7 M urea in TE was added to inactivate the protease. The RNA was phenol extracted, precipitated with ethanol and separated of 5% polyacrylamide gels containing 8 M urea in TBE. Human p53 protein was overproduced in insect cells and three dierent forms were separated as described . Brie¯y, insect cell lysates containing p53 were applied to a heparin-Sepharose column (HiTrap, Pharmacia) at a ratio of protein (mg) to resin (ml) of 0.5 to 1.0. The bound protein was eluted with a 20 ml linear gradient from 0.05 M KCl to 1 M KCl in buer B (20% glycerol, 25 mM HEPES (pH 7.6), 0.1 mM EDTA, 5 mM DTT, 1 mM benzamidine and 0.1% Triton X-100). Fractions were collected (one-tenth of the column volume) and assayed for DNA binding without and with PAb421. PAb421 non-reactive, activated p53 eluted earlier than PAb421 reactive, latent p53
Puri®cation of p53 by heparin-Sepharose chromatography and elution with a salt gradient yielded fractions of p53 with distinguishable properties (Hupp et al., 1992) , activated and latent p53. Activated p53 tends to elute at lower salt concentrations (Figure 3a , fraction A); it is de®ned by its ablity to bind to a p53 DNA response element in a bandshift assay (Figure 3a , lane 1). The p53 DNA complex can be recognized and supershifted by PAb1801 (lane 3), but not by PAb421 (lane 2). The latent p53 fraction elutes at higher salt concentrations (Figure 3 , fraction E contains mainly latent p53); it is de®ned by its inability to form a DNA (Hupp et al., 1992) (Figure 2 ) and bandshift analyses were carried out with a radioactively labeled BC probe in the absence and presence of the monoclonal antibodies PAb421 and PAb1801. Fraction A (activated p53) and fraction E (latent p53) were dephosphorylated by a mixture of PP-2A and PP-1 phosphatases. Fraction A gained latency by dephosphorylation. DNA protein binding was carried out in 20 microliter volume and ®nal concentrations of 50 mM Tris pH 7.9, 50 mM NaCl 4% glycerol, 2 mM DTT, 0.5 mM MgCl 2 , 0.05% Triton X-100. 2.5 microgram unspeci®c competitor DNA (poly d(AT), Boehringer, Mannheim) and 1 microgram BSA per binding reaction were added. The p53 speci®c probe was prepared by annealing of the single-stranded oligonucleotides which contain a BC element . The double-stranded oligonucleotides were gel puri®ed. Preincubation with antibodies was for 30 min at room temperature. Binding to the labeled DNA probe was for 30 min at room temperature. Separation of the complexes was carried out on a 5% polyacrylamide gel in 0.256TBE. Hupp et al., 1992 Hupp et al., , 1993 . The speci®city of the DNA-p53 complex formation was shown in oligonucleotide competition experiments. A 50-fold molar excess of non-radioactive BC oligonucleotide included in the reaction shown in lane 1 prevented the complex formation between activated p53 and the radioactive DNA probe. Also, no bandshift signal was observed when non-radioactive BC was added to the reaction shown in lane 17, in which latent p53 and PAb421 were present (not shown).
Dephosphorylation of activated p53 converts it into the latent form
The epitope for PAb421 is located within a consensus sequence phosphorylated by protein kinase C (Ullrich et al., 1992; Hupp and Lane, 1994b) . It is therefore not unreasonable to assume that the dierence between latent and activated p53 could lie in the phosphorylation status of the PKC site. We tested this notion and dephosphorylated activated p53 (fraction A in Figure  3 ) with a mixture of protein phosphatase-2A (PP-2A) and protein phosphatase-1 (PP-1). Dephosphorylation led to a drastic loss of DNA binding (Figure 3, lane  19) . This loss was concomitant with the acquisition of PAb421 binding potential (lane 22) . This experiment suggests that dephosphorylated p53 corresponds to the latent form. The conclusion was corroborated by an unde®ned Sf9 kinase acting upon bacterial p53 in vitro (Figure 3b ). Three variants of p53, the full length protein, a deletion mutant lacking the carboxylterminal 60 amino acids and a fragment consisting of amino acids 302 to 393 were expressed in E. coli, puri®ed and phosphorylated in vitro by a crude Sf9 cell extract. The conditions were chosen to favor activity by PKC. In vitro phosphorylation of the full length molecule (lane 1) and the carboxyl terminal fragment (lane 3) were observed. The deletion mutant D326 was not phosphorylated (lane 2). This indicates that Sf9 derived p53 is phosphorylated on its carboxylterminus and that Sf9 cells express a PKC-like activity which can phosphorylate this region.
In vitro transcription with the activated form of p53
We used the activated form of p53 (shown in Figure  3a , fraction A) in in vitro transcription experiments. This form is characterized by its ability to bind to the p53 response element, form a DNA complex in a bandshift experiment and can be recognized by PAb1801, but not by PAb421. In vitro transcription of BC300 is stimulated by activated p53 (Figure 4a and  b, lanes 1 to 5) . The induction of transcription is not aected by the inclusion of increasing amounts of PAb421 (lanes 2 to 5). This is not true for PAb1801. This antibody recognizes activated p53 in its DNA bound form and inhibits induction of transcription (lane 9). A control antibody directed against the transcription factor Stat3 had no eect (lane 10).
We assayed the activity of the phosphatase inhibitor okadaic acid on the in vitro transcription reaction. Inhibition of phosphatases, possibly present in the rat liver nuclear extract, did not alter the transcriptional activation by p53 (Figure 4a and b, lanes 7 and 8) . Inclusion of the BC oligonucleotide (p53 response element) suppressed p53 mediated induction, but not AdML promoter directed transcription (lanes 11 and 12).
The latent form of p53 can be activated in the in vitro transcription reaction by PAb421
We also introduced the latent form of p53 (shown in Figure 3a , fraction E) into in vitro transcription reactions. This form is not able to bind to the p53 response element in the absence of auxiliary factors and no DNA complex can be observed in bandshift experiments. Upon association with PAb421 latent p53 is converted into a DNA binding form and a supershifted DNA complex can be observed. A very weak stimulation of in vitro transcription of BC300 can be observed when latent p53 is added to the reaction (Figure 5a and b, lanes 1 and 2) . It is probable that this increase in transcription is due to contaminating activated p53 in fraction E (see Figure 3a , lane 15: residual activated p53, supershifted by PAb1801). The association of latent p53 with PAb421 leads to induction of BC300 transcription, but has no eect on AdML200 transcription (lanes 3 and 4) . An antibody recognizing Stat3 is not able to aect the induction (lanes 5 and 6). Induction is suppressed by inclusion of BC oligonucleotide (p53 response element) (lanes 7 and 8), but not by an oligonucleotide without p53 binding sites (lanes 9 and 10).
When activated p53 is dephosphorylated by PP-2A and PP-1 it looses its constitutive DNA binding ability and gains the capacity to bind to PAb421 (Figure 3a , lanes 19 and 20). We also treated latent p53 with PP-2A and PP-1 (Figure 3a , lanes 21 and 22) and introduced it into the in vitro transcription reaction in the absence and presence of PAb421 (Figure 6a and b). The dephosphorylated p53 (lanes 5 to 8) was as well able to induce transcription in the presence of PAb421 as the non-dephosphorylated form (lanes 1 to 4). This is a further indication that the site dephosphorylated by PP-2A and PP-1 is the site where PAb421 binds and that binding of PAb421 can functionally mimick the phosphorylation event.
We investigated two forms of p53 which are found in insect cells infected with a baculovirus encoding p53. Puri®cation by heparin-Sepharose column chromatography and elution of the bound material with a salt gradient yielded fractions of p53 which can be distinguished in their DNA binding activities and their reactivity with the monoclonal antibody PAb421 (Hupp et al., 1992; Hupp and Lane, 1994a) . The correlation of DNA binding and reactivity with PAb421 suggested that the fractions dier in Cterminal modi®cations, possibly phosphorylation. Baculovirus encoded proteins expressed in insect cells are often phosphorylated. Our experiments show that the insect cells express a PKC-like activity which is able to phosphorylate the C-terminal domain of p53 in vitro. Latent and activated p53 were compared with respect to their DNA binding activity and their transactivation potential.
Latent p53 is not able to bind to DNA or to transactivate a promoter reporter construct in the absence of auxiliary factors. Latent p53 can be activated by the antibody PAb421. The binding of the monoclonal antibody PAb421 to latent p53 converts the protein into a DNA binding form. This form is able to transactivate a reporter gene construct. Distinct DNA binding and transactivation domains are present in many transcription factors and multiple mechanisms have been discovered by which these domains are regulated. Independent signaling pathways are often found which dierentially aect DNA binding and transactivation. The ability of PAb421 to regulate both suggests that the induction of a conformational change is the limiting aspect in p53 function.
The presence of a latent form of p53 in cultured, mammalian cells seems likely. An activation step might precede the slow accumulation of endogenous p53 32 PUTP-labeled RNA expressed in the in vitro transcription assay. The assay conditions are the same as described in Figure 2 . The fraction used for the assay is fraction E shown in bandshift assay in Figure 3 . (b) Quantitative measurement of the radioactive RNA bands by phosphoimaging levels, e.g. after DNA damage by u.v. irradiation, and provide the means for an immediate early response. Microinjection experiments with PAb421 into cultured cells are also indicative of the latent form because endogenous p53 is activated by the antibody (Abarzua et al., 1995; . Modi®cation of its Cterminus could also be the mechanism for transcriptional activation in vivo. Dierent reactivities of p53 with PAb421 have been observed in the phases of the cell cycle. In the G0 phase, p53 is present in a form which does not bind to PAb421, possibly the activated form. After serum induction of the cells, p53 is converted in G1 to the PAb421 binding form, possibly the latent form (Milner and Watson, 1990) . Reversible phosphorylation-dephosphorylation events, occuring during the cell cycle, could be responsible. Additional mechanisms have been described which relieve repression of DNA binding. PKC isozymes can phosphorylate p53 in vitro at the C-terminus (Baudier et al., 1992; Hupp and Lane, 1994b; Takenaka et al., 1995;  own observations) and induce DNA binding. PKC mediated phosphorylation in p53 activation in vivo has been discussed (Milne et al., 1996; Delphin et al., 1994; Hupp and Lane, 1994b) .
Kinase action, dierential splicing or translation, interaction with other cellular proteins and nucleic acid fragments could act as regulatory components in the activation of p53 (Bakalin et al., 1994; Jayaramean and Prives, 1995; Bayle et al., 1994; Molinari and Milner, 1995; Wang et al., 1996) . In vitro transcription allows to test which interactions are responsible for the conversion of latent into transcriptionally active forms of p53 and to show that a carboxyl terminal protein interaction is sucient. At this point we can functionally distinguish at least three forms of p53: a transcriptionally active form which may in vivo mediate G1 arrest via transcription of the gene for the CDK inhibitor p21; a form which is not transcriptionally active on this gene promoter, but capable to induce apoptosis (Wang et al., 1996) and a latent form not yet committed to either pathway. The ®rst two forms of p53 may bind to p53 DNA response elements but the third form does not bind to DNA without further activation. Latent p53 may be directed to assume dierent functions by alternative mechanisms of activation, for example by interaction with a cellular equivalent of PAb421 or helicases involved in the induction of apoptosis (Wang et al., 1996) . These results encourage attempts to develop compounds which target the carboxyl terminus of mutant p53 variants and activate the molecule for therapeutic purposes (Abarzua et al., 1995) . A manipulation of the carboxyl terminus may either lead to G1 arrest by mimicking the Pab421 activity or to apoptosis. Figure 6 Dephosphorylated latent p53 can be activated by PAb421. The fraction used for the assay is fraction E shown in bandshift assay in Figure 3 . Three units of protein phosphatase 2A (PP-2A) and protein phosphatase 1 (PP-1, Gibco-BRL) were incubated with p53 (0.1 microgram) for 10 min at 308C and 20 min at room temperature. Okadaic acid was added to a ®nal concentration of 20 nM. The activity of the phosphatase was con®rmed in a bandshift assay by dephosphorylation of activated p53 (fraction A in Figure 3 ) which gained latency and was supershifted by the antibody PAb421 (Figure 3 ). The numbering of the lanes in a and the bars in b relate to the same experiment.
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